Fujifilm Diosynth announces the inception of its FDB center of excellence in bioprocessing 2.0 to extend its bioprocessing innovations with a network of researchers.
Active competition law enforcement is encouraging the pharmaceutical industry to provide more affordable medicines and promotes innovation, suggests EC report.
In another blow to discovering a treatment for Alzheimer’s, Roche revealed that preliminary data from two clinical trials meant it was cancelling studies using crenezumab.
The explosion of the gene therapy industry is leading to supply issues, which has led one company to view producing its own clinical materials as its best option.
The contract market for bringing biologics through the pipeline to commercialisation is growing at a rapid clip, with a recent report suggesting a high CAGR in the sector.
GE Healthcare and G-CON have combined capabilities to offer drug developers ‘readily deployable’ manufacturing platforms for cell therapies and viral vectors.
